Stagezero Life Sciences (OTCMKTS:SZLSF – Get Free Report) and TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.
Insider and Institutional Ownership
2.6% of TriSalus Life Sciences shares are held by institutional investors. 2.5% of Stagezero Life Sciences shares are held by insiders. Comparatively, 27.5% of TriSalus Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Risk and Volatility
Stagezero Life Sciences has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Stagezero Life Sciences | N/A | N/A | N/A | ($0.01) | -0.05 |
| TriSalus Life Sciences | $29.43 million | 10.36 | -$30.05 million | ($2.02) | -3.02 |
Stagezero Life Sciences has higher earnings, but lower revenue than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Stagezero Life Sciences, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Stagezero Life Sciences and TriSalus Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Stagezero Life Sciences | N/A | N/A | N/A |
| TriSalus Life Sciences | -98.45% | N/A | -111.88% |
Analyst Ratings
This is a summary of recent recommendations for Stagezero Life Sciences and TriSalus Life Sciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Stagezero Life Sciences | 0 | 0 | 0 | 0 | 0.00 |
| TriSalus Life Sciences | 1 | 1 | 3 | 0 | 2.40 |
TriSalus Life Sciences has a consensus target price of $11.00, suggesting a potential upside of 80.33%. Given TriSalus Life Sciences’ stronger consensus rating and higher possible upside, analysts plainly believe TriSalus Life Sciences is more favorable than Stagezero Life Sciences.
Summary
TriSalus Life Sciences beats Stagezero Life Sciences on 7 of the 11 factors compared between the two stocks.
About Stagezero Life Sciences
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company’s lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual’s current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman’s risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.
About TriSalus Life Sciences
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
Receive News & Ratings for Stagezero Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stagezero Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
